ISSN: 2692-5206
AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

EFFECTIVE USE OF HORMONAL THERAPY IN LUPUS ERYTHEMATOSUS

D.R. Abdullayeva[1], I.Sh. Bobojonov[2]

Abstract: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that primarily affects women, suggesting a role of sex hormones in its pathogenesis. Hormonal therapy, particularly corticosteroids, remains a cornerstone in SLE management. Additionally, sex hormones such as estrogens and androgens have been investigated for their effects on disease activity. While estrogen is known to promote autoimmune responses, androgens may have immunosuppressive effects. This article explores the mechanisms, clinical applications, benefits, and risks of hormonal therapy in lupus. The role of corticosteroids, hormone replacement therapy (HRT), oral contraceptives, and androgens such as dehydroepiandrosterone (DHEA) is examined. A balanced approach is necessary to maximize therapeutic benefits while minimizing risks.

Key words: Systemic lupus erythematosus, hormonal therapy, corticosteroids, estrogen, androgens, DHEA, immunomodulation.

Introduction

Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by widespread inflammation and multi-organ involvement. It predominantly affects women of reproductive age, with a female-to-male ratio of approximately 9:1 (Ortona et al., 2016). This gender disparity has led researchers to investigate the role of sex hormones, particularly estrogen and androgens, in lupus pathogenesis.

Hormonal therapy plays a crucial role in SLE management. Corticosteroids, such as prednisone, have been the mainstay of treatment for decades, providing potent anti-inflammatory effects. However, prolonged corticosteroid use is associated with significant adverse effects, necessitating careful dose management and adjunct therapies.

Beyond corticosteroids, hormonal interventions such as hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), oral contraceptives, and androgen supplementation have been explored as potential therapeutic strategies in lupus patients. This article reviews the effectiveness, risks, and clinical applications of hormonal therapy in lupus treatment.

Corticosteroids in Lupus Therapy

Mechanism of Action

Corticosteroids exert their effects by:

Suppressing pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α).

Inhibiting T-cell activation and proliferation.

ISSN: 2692-5206
AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

Reducing autoantibody production by B cells.

Indications and Clinical Use

Corticosteroids are used in SLE for:

Acute disease flares: High-dose intravenous methylprednisolone (1 g/day for 3 days) is used in severe lupus manifestations, such as lupus nephritis and neuropsychiatric lupus.

Chronic management: Low-dose prednisone (5–10 mg/day) helps control mild-to-moderate disease activity.

Steroid-sparing strategies: To minimize corticosteroid side effects, they are often combined with immunosuppressants like methotrexate, azathioprine, or mycophenolate mofetil.

Minimizing Side Effects

Long-term corticosteroid use can lead to osteoporosis, diabetes, hypertension, and cardiovascular disease. Strategies to reduce these risks include:

Tapering corticosteroid doses to the lowest effective level.

Using steroid-sparing agents to reduce dependency.

Supplementing with calcium, vitamin D, and bisphosphonates to prevent bone loss.

Estrogen and Hormone Replacement Therapy (HRT)

Role of Estrogen in Lupus Pathogenesis

Estrogen influences immune function by:

Enhancing B-cell activation and increasing autoantibody production.

Stimulating type I interferon activity, a key driver of lupus pathogenesis (Petri et al., 2018).

HRT and Lupus Disease Activity

The use of HRT in postmenopausal lupus patients remains controversial. While some studies suggest that low-dose HRT does not significantly increase disease activity, others highlight an increased risk of thrombotic events, particularly in patients with antiphospholipid syndrome (APS) (Buyon et al., 2005).

Oral Contraceptives in SLE

ISSN: 2692-5206
AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

Estrogen-containing contraceptives: Once thought to exacerbate lupus, recent studies suggest they can be safely used in patients with stable disease and no history of thrombosis.

Progestin-only contraceptives: A safer alternative for lupus patients at high thrombotic risk.

Selective Estrogen Receptor Modulators (SERMs): Agents such as raloxifene may provide estrogenic benefits without worsening lupus activity.

Androgens and DHEA Therapy

Immunomodulatory Effects of Androgens

Androgens, such as testosterone and dehydroepiandrosterone (DHEA), have immunosuppressive properties, including:

Inhibiting B-cell proliferation and autoantibody production.

Reducing pro-inflammatory cytokine levels.

Enhancing regulatory T-cell function.

Clinical Benefits of DHEA in Lupus

DHEA, a weak androgen, has been studied as a potential adjunct therapy in lupus. Clinical trials suggest that DHEA supplementation (200 mg/day) may:

Reduce corticosteroid requirements.

Improve fatigue and overall well-being.

Enhance bone density, reducing osteoporosis risk.

However, potential side effects of DHEA include acne, hirsutism, and alterations in lipid metabolism. Its use should be individualized based on patient tolerance and disease severity (van Vollenhoven et al., 1999).

Future Directions in Hormonal Therapy for SLE

Ongoing research is exploring novel hormonal approaches for SLE management, including:

Selective estrogen receptor modulators (SERMs) that provide beneficial estrogenic effects without exacerbating autoimmunity.

Androgen analogs with enhanced immunosuppressive properties and fewer androgenic side effects.

ISSN: 2692-5206
AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

Targeted hormonal therapies that modulate immune responses without increasing cardiovascular risk.

Conclusion

Hormonal therapy plays a critical role in lupus treatment, with corticosteroids remaining the primary therapeutic option. Estrogen-modulating strategies, such as HRT and oral contraceptives, require careful patient selection due to potential thrombotic risks. Androgen-based therapies, particularly DHEA supplementation, offer promising benefits in reducing corticosteroid dependence and improving quality of life.

A personalized approach is essential when considering hormonal therapy for SLE patients, balancing therapeutic efficacy with potential risks. Future research on selective hormonal modulation may provide safer and more effective treatment strategies for lupus management.

References

1. Buyon, J. P., et al. (2005). The effects of combined oral contraceptives on disease activity in systemic lupus erythematosus. New England Journal of Medicine, 353(24), 2550-2558.

2. Ortona, E., Pierdominici, M., & Maselli, A. (2016). Sex hormones and autoimmunity: Implications for SLE. Current Opinion in Rheumatology, 28(6), 598-603.

3. Petri, M., et al. (2018). Estrogen metabolism and SLE risk. Arthritis & Rheumatology, 70(7), 1061-1067.

4. van Vollenhoven, R. F., et al. (1999). Treatment of mild-to-moderate SLE with dehydroepiandrosterone. Arthritis & Rheumatology, 42(1), 76-84.